Guggenheim Reiterates Buy on Compass Therapeutics, Maintains $12 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 87.4%

Neg 0% Neu 87.4% Pos 0%

Guggenheim analyst Michael Schmidt reiterates Compass Therapeutics (NASDAQ:CMPX) with a Buy and maintains $12 price target.